Clinical trials: Hyperuricemia With or Without Gout
Hyperuricemia
Study of FYU-981 in Hyperuricemia With or Without Gout
The purpose of this study is exploratory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered…
- Trial name
- NCT02344862
- Testing
- FYU-981 High dose, (Oral daily dosing for 8 weeks), FYU-981 Middle dose, (Oral daily dosing for 8 weeks), FYU-981 Low dose, (Oral daily dosing for 8 weeks)
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Fuji Yakuhin Co., Ltd.
Hyperuricemia
Zurig (Febuxostat) 40mg Efficacy and Safety Trial
Febuxostat is a potent, nonpurine, selective inhibitor of Xanthine oxidase that exhibits antihyperuricemic activity by reducing the formation of uric acid.
- Trial name
- ZEST (NCT02600780)
- Testing
- Febuxostat, Allopurinol
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Getz Pharma
Diabetic Nephropathy
Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
The purpose of this study is to investigate the effect of topiroxostat on urinary albumin excretion and the safety in patients with early stage diabetic nephropathy and hyperuricemia with or without gout.
- Trial name
- UPWARD (NCT02327754)
- Testing
- Topiroxostat BID, (Oral daily dosing for 28 weeks)
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Hyperuricemia With or Without Gout
Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult Subjects
The study is to evaluate the impact of food on the pharmacokinetics of F-02-2-Na in healthy adult subjects by observing the changes in the drug's pharmacokinetic profile-particularly in its absorption process-before and after…
- Trial name
- NCT07346027
- Testing
- Fasting administration of F-02-2-Na (50mg) - Fed administration of F-02-2-Na (50mg), Fed administration of F-02-2-Na (50mg) - Fasting administration of F-02-2-Na (50mg)
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.
Hyperuricemia With or Without Gout
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized…
- Trial name
- NCT03372200
- Testing
- FYU-981, Febuxostat
- Where
- Japan
- Volunteers
- 203 people
- Sponsor
- Mochida Pharmaceutical Company, Ltd.
Hyperuricemia With or Without Gout
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects
The primary objective of this study is to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of ascending single orally administered doses of F-02-2-Na in adult subjects (to include the Mass Balance) \& multiple…
- Trial name
- NCT07324434
- Testing
- F-02-2-Na Tablet (0.5 mg), F-02-2-Na Tablet (5 mg), F-02-2-Na Tablet (10 mg)
- Where
- China
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.
Hyperuricemia With or Without Gout
Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
FYU-981 or Benzbromarone are administrated to hyperuricemia patients with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose…
- Trial name
- NCT03100318
- Testing
- FYU-981, Benzbromarone
- Where
- Japan
- Volunteers
- 201 people
- Sponsor
- Fuji Yakuhin Co., Ltd.
Hyperuricemia With or Without Gout
Study of FYU-981 in Hyperuricemia With or Without Gout
The purpose of this study is confirmatory investigation of safety and efficacy of FYU-981 administered orally to hyperuricemic patients with and without gout for 34 or 58 weeks by the method of multicenter, open label and…
- Trial name
- NCT03006445
- Testing
- FYU-981
- Where
- Japan
- Volunteers
- 330 people
- Sponsor
- Fuji Yakuhin Co., Ltd.
Hyperuricemia With or Without Gout
Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
To investigate the pharmacodynamics and safety of FYU-981 administered orally once a day for 14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male hyperuricemic outpatients with or without gout.
- Trial name
- NCT03375632
- Testing
- FYU-981
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Mochida Pharmaceutical Company, Ltd.
Hyperuricemia
Study of FYU-981 in Hyperuricemia With or Without Gout
The purpose of this study is confirmatory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered…
- Trial name
- NCT02416167
- Testing
- FYU-981
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Fuji Yakuhin Co., Ltd.